IP Library Granted Patent US 11,674,135
Granted Patent B2
US 11,674,135 · App. 14/414,326 · Granted Jun 13, 2023

DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases

Inventors: Anthony D. Keefe (Cambridge, MA); Alexander Litovchick (Sudbury, MA); Matthew Clark (Lexington, MA)
Assignee: X-Chem, Inc.
C12N15/1065C12N15/1044C12N15/1068C12Q1/6869
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,674,135
App. No.
14/414,326
Granted
Jun 13, 2023
Kind
B2
Abstract

The present invention relates to complexes of oligonucleotide-encoded libraries and methods of tagging and using such libraries. In particular, the oligonucleotides and methods can include complexes having at least one linkage for which a polymerase has reduced ability to read or translocate through.

Claims (17)

1. A complex comprising:

(i) a chemical entity comprising one or more scaffolds or one or more building blocks;

(ii) a headpiece having a first functional group operatively associated with said chemical entity and a second functional group operatively associated with an a first oligonucleotide tag via a first linkage;

(iii)-n number of additional oligonucleotide tags having n additional linkages, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and wherein each of said additional linkages is between two adjacent tags and each tag encodes the identity of at least one of said one or more scaffolds or building blocks; and

wherein at least one of said n additional linkages is a cross-linking oligonucleotide that spans the junction between two adjacent tags, and that operatively associates with said two adjacent tags via one or more reversible co-reactive groups, wherein at least one of said one or more reversible co-reactive groups is a cyanovinylcarbazole.

2. The complex of claim 1 , wherein at least two of said first linkage and n additional linkages comprise:

a cross-linking oligonucleotide that spans the junction between said second functional group and said first tag or between two adjacent tags and that operatively associates with said second functional group and said first tag or with said two adjacent tags via one or more reversible co-reactive groups, wherein at least one of said one or more reversible co-reactive groups is a cyanovinylcarbazole.

3. The complex of claim 1 or 2 , wherein one or more tags comprise a 5′-connector at the 5′-terminus of said one or more tags and a 3′-connector at the 3′-terminus of said one or more tags.

4. The complex of claim 1 , wherein less than about 50% of said first linkage and n additional linkages comprise an enzymatic linkage.

5. The complex of claim 1 , wherein said chemical entity is operatively associated to said headpiece via a bifunctional spacer.

6. The complex of claim 1 , wherein said chemical entity is covalently attached to said headpiece.

7. The complex of claim 1 , wherein said headpiece comprises an oligonucleotide selected from the group consisting of a double-stranded oligonucleotide, a single-stranded oligonucleotide, or a hairpin oligonucleotide.

8. The complex of claim 7 , wherein said headpiece comprises a primer-binding region.

9. The complex of claim 1 , further comprising one or more first library-identifying tag(s), use tag(s), and/or origin tag(s).

10. The complex of claim 1 , wherein said complex comprises RNA, DNA, modified DNA, and/or modified RNA.

11. The complex of claim 1 , further comprising a tailpiece.

12. A library comprising one or more complexes of claim 1 .

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 15, 2021
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: JAGUAR HOLDING COMPANY I; JAGUAR HOLDING COMPANY II; PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
Reel/Frame 054931/0201 →
SECURITY INTEREST Recorded Dec 11, 2020
From: X-CHEM, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 054619/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2017
From: KEEFE, ANTHONY D.; LITOVCHICK, ALEXANDER; CLARK, MATTHEW
To: X-CHEM, INC.
Reel/Frame 041157/0843 →
RELEASE OF SECURITY INTEREST Recorded Jan 20, 2016
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: X-CHEM, INC.
Reel/Frame 037534/0983 →
SECURITY AGREEMENT Recorded Sep 2, 2015
From: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC; PPD DEVELOPMENT, L.P.; PHARMACO INVESTEMENTS, INC.; X-CHEM, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 036528/0004 →
RELEASE OF SECURITY INTEREST Recorded Sep 2, 2015
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC; PPD DEVELOPMENT, L.P.; PHARMACO INVESTEMENTS, INC.; X-CHEM, INC.
Reel/Frame 036481/0051 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT Recorded Jun 12, 2015
From: X-CHEM, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 035900/0365 →
Continuity (2)
Provisional Application 61671406 · Jul 13, 2012
Related Publication 20150211002A1 · Jul 30, 2015